https://www.pharmaradar360.com/article/dhsc-workforce-management-information-62f452371af74327PharmaRadar360en2026-09-24T11:12:11.000ZDHSC: workforce management informationhttps://www.pharmaradar360.com/article/dhsc-workforce-management-information-august-2026-291cf16d23181a61PharmaRadar360en2026-09-24T11:11:46.000ZDHSC: workforce management information August 2026https://www.pharmaradar360.com/article/a-second-measure-favored-the-higher-dose-the-alzheimer-s-drug-narrowly-missed-it-3c1bb4ef41c89852PharmaRadar360en2026-09-24T11:03:43.000ZA second measure favored the higher dose. The Alzheimer’s drug narrowly missed its main test.https://www.pharmaradar360.com/article/healthy-start-extension-application-guidance-84d59c59b495a9a2PharmaRadar360en2026-09-24T10:58:31.000ZHealthy Start extension: application guidancehttps://www.pharmaradar360.com/article/enveda-nabs-311m-to-progress-nature-derived-drug-pipeline-55af799b19cd9116PharmaRadar360en2026-09-24T10:52:37.000ZEnveda nabs $311m to progress nature-derived drug pipelinehttps://www.pharmaradar360.com/article/ctt-pharmaceutical-adds-karen-larson-to-board-e7cff323c616d17fPharmaRadar360en2026-09-24T10:49:11.000ZCTT Pharmaceutical Adds Karen Larson to Boardhttps://www.pharmaradar360.com/article/merck-s-remigromig-a-tri-specific-agonist-of-the-wingless-related-integration-si-564f990f527f019dPharmaRadar360en2026-09-24T10:45:00.000ZMerck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edemahttps://www.pharmaradar360.com/article/lilly-s-fda-approved-weekly-insulin-could-mean-over-300-fewer-shots-a-year-than-a8e09cc6f5e4003aPharmaRadar360en2026-09-24T10:45:00.000ZLilly's FDA-approved weekly insulin could mean over 300 fewer shots a year than daily insulinhttps://www.pharmaradar360.com/article/gohub-ventures-invests-in-swiss-biotech-startup-prevision-medicine-5b7fe1d6af0950f2PharmaRadar360en2026-09-24T10:36:47.000ZGoHub Ventures invests in Swiss biotech startup Prevision Medicinehttps://www.pharmaradar360.com/article/why-gilead-can-t-stop-talking-about-its-ambitions-in-immunology-4e9a973d5ffa33b5PharmaRadar360en2026-09-24T10:34:09.000ZWhy Gilead can’t stop talking about its ambitions in immunologyhttps://www.pharmaradar360.com/article/working-for-dhsc-7fde6c0568507ce7PharmaRadar360en2026-09-24T10:31:18.000ZWorking for DHSChttps://www.pharmaradar360.com/article/krystal-biotech-stock-initiated-at-buy-by-goldman-sachs-06ed5dbd214c1bc0PharmaRadar360en2026-09-24T10:26:45.000ZKrystal Biotech stock initiated at buy by Goldman Sachshttps://www.pharmaradar360.com/article/podcast-how-sandoz-plans-to-harness-its-golden-decade-68b53bc08b1c1d6fPharmaRadar360en2026-09-24T10:25:23.000ZPodcast: How Sandoz plans to harness its "golden decade"https://www.pharmaradar360.com/article/what-actually-went-wrong-when-a-phase-3-trial-fails-q-a-with-dr-remo-moomiaie-qa-c88ca5967f76fd20PharmaRadar360en2026-09-24T10:06:38.000ZWhat Actually Went Wrong When a Phase 3 Trial Fails: Q&A with Dr. Remo Moomiaie-Qajarhttps://www.pharmaradar360.com/article/china-is-excelling-in-health-tech-that-s-good-news-for-the-world-30d79eb43ed47a25PharmaRadar360en2026-09-24T10:05:26.000ZChina is excelling in health tech. That’s good news for the worldhttps://www.pharmaradar360.com/article/0a2b89983de35c79PharmaRadar360en2026-09-24T10:02:05.000ZΠροσωρινός πίνακας κατάταξης υποψηφίων συνεργατών του ΕΟΦ με καθεστώς ΑΠΥ ειδικότητας ΔΕ Οδηγώνhttps://www.pharmaradar360.com/article/schorr-family-foundation-scholarships-help-two-pharmacy-students-c82a687b573f5292PharmaRadar360en2026-09-24T10:00:38.000ZSchorr Family Foundation Scholarships help two pharmacy studentshttps://www.pharmaradar360.com/article/fda-and-atyr-align-on-a-planned-lung-disease-drug-trial-for-up-to-about-372-pati-f7ff287b591c8a1ePharmaRadar360en2026-09-24T10:00:00.000ZFDA and aTyr align on a planned lung disease drug trial for up to about 372 patients.https://www.pharmaradar360.com/article/2026-909-27-2026-c0fc667f86e8537cPharmaRadar360en2026-09-24T09:56:36.000ZΑνακοίνωση σχετικά με τον ΚΑΝΟΝΙΣΜΟ (ΕΕ) 2026/909 ΤΗΣ ΕΠΙΤΡΟΠΗΣ της 27ης Απριλίου 2026https://www.pharmaradar360.com/article/why-biotech-has-a-lot-riding-on-trump-s-fda-pick-7b6780f9008f70f9PharmaRadar360en2026-09-24T09:49:57.000ZWhy biotech has a lot riding on Trump's FDA pickhttps://www.pharmaradar360.com/article/caliway-reports-phase-ii-success-for-dercum-s-disease-therapy-d74330c3d4bd909cPharmaRadar360en2026-09-24T09:45:00.000ZCaliway reports Phase II success for Dercum's disease therapyhttps://www.pharmaradar360.com/article/a-visual-guide-to-vaccines-9bd59f2f55e933f2PharmaRadar360en2026-09-24T09:26:47.000ZA visual guide to vaccineshttps://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-tkno-mrna-atrc-ilmn-db25e51232f70ef0PharmaRadar360en2026-09-24T09:26:00.000ZBiotech Stocks At 52-Week Highs - TKNO, MRNA, ATRC, ILMNhttps://www.pharmaradar360.com/article/basecamp-research-secures-140m-for-ai-driven-therapies-1fb496172a1d55e7PharmaRadar360en2026-09-24T09:15:40.000ZBasecamp Research secures $140m for AI-driven therapieshttps://www.pharmaradar360.com/article/saudi-arabia-s-1-3-billion-biotech-push-following-riyadh-summit-1a760444b9610383PharmaRadar360en2026-09-24T09:05:00.000ZSaudi Arabia’s $1.3 billion biotech push following Riyadh summithttps://www.pharmaradar360.com/article/cspc-pharmaceutical-initiates-phase-iii-trial-of-hb1801-for-advanced-breast-canc-722961134acadef9PharmaRadar360en2026-09-24T09:04:41.000ZCSPC Pharmaceutical Initiates Phase III Trial Of HB1801 For Advanced Breast Cancer In Chinahttps://www.pharmaradar360.com/article/abortion-pills-vaccines-and-food-safety-f-d-a-nominee-heidi-overton-faces-senate-8657d6ea819eb9f9PharmaRadar360en2026-09-24T09:02:43.000ZAbortion Pills, Vaccines and Food Safety: F.D.A. Nominee Heidi Overton Faces Senate Confirmation Hearinghttps://www.pharmaradar360.com/article/japan-s-kobayashi-pharmaceutical-considering-going-private-under-japan-uk-invest-b7d7019e91da6c88PharmaRadar360en2026-09-24T09:01:56.000ZJapan's Kobayashi Pharmaceutical Considering Going Private Under Japan-UK Investment Fund Consortium, Bloomberg News Sayshttps://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharmaRadar360en2026-09-24T09:01:04.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/daewoong-pharmaceutical-presents-baseline-characteristics-of-104-patients-in-glo-9e2412cd0063c035PharmaRadar360en2026-09-24T08:44:00.000ZDaewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026https://www.pharmaradar360.com/article/pre-release-access-lists-cover-programme-quarterly-data-428cef6b96303d41PharmaRadar360en2026-09-24T08:30:20.000ZPre-release access lists: COVER programme quarterly datahttps://www.pharmaradar360.com/article/pseudomonas-aeruginosa-bacteraemia-annual-data-1d797b39720d627dPharmaRadar360en2026-09-24T08:30:18.000ZPseudomonas aeruginosa bacteraemia: annual datahttps://www.pharmaradar360.com/article/mssa-bacteraemia-annual-data-f528c463d0bdaf78PharmaRadar360en2026-09-24T08:30:17.000ZMSSA bacteraemia: annual datahttps://www.pharmaradar360.com/article/klebsiella-species-bacteraemia-annual-data-503a503e52f5c85bPharmaRadar360en2026-09-24T08:30:17.000ZKlebsiella species bacteraemia: annual datahttps://www.pharmaradar360.com/article/clostridioides-difficile-c-difficile-infection-cdi-annual-data-8aca3e044b7619f2PharmaRadar360en2026-09-24T08:30:17.000ZClostridioides difficile (C difficile) infection (CDI): annual datahttps://www.pharmaradar360.com/article/escherichia-coli-bacteraemia-annual-data-3f475f96b5a9b5cbPharmaRadar360en2026-09-24T08:30:16.000ZEscherichia coli bacteraemia: annual datahttps://www.pharmaradar360.com/article/survey-of-adult-carers-in-england-d418d708ba824a58PharmaRadar360en2026-09-24T08:30:16.000ZSurvey of adult carers in Englandhttps://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-surveillance-reports-2026-to-2027-season-1cc078fa257f8153PharmaRadar360en2026-09-24T08:30:11.000ZNational norovirus and rotavirus surveillance reports: 2026 to 2027 seasonhttps://www.pharmaradar360.com/article/group-a-streptococcal-infections-seasonal-activity-in-england-2025-to-2026-ce123cc7682acde2PharmaRadar360en2026-09-24T08:30:11.000ZGroup A streptococcal infections: seasonal activity in England, 2025 to 2026https://www.pharmaradar360.com/article/salmonella-statistical-releases-5659a2d745797007PharmaRadar360en2026-09-24T08:30:10.000ZSalmonella statistical releaseshttps://www.pharmaradar360.com/article/gastrointestinal-infections-and-outbreak-statistics-for-england-05961f6c3dda1ec2PharmaRadar360en2026-09-24T08:30:10.000ZGastrointestinal infections and outbreak statistics for Englandhttps://www.pharmaradar360.com/article/childhood-vaccine-coverage-provisional-monthly-data-england-2026-29f210faf64d1d4dPharmaRadar360en2026-09-24T08:30:10.000ZChildhood vaccine coverage: provisional monthly data (England) 2026https://www.pharmaradar360.com/article/staphylococcus-aureus-guidance-data-and-analysis-a8912dd7bdb60a2dPharmaRadar360en2026-09-24T08:30:10.000ZStaphylococcus aureus: guidance, data and analysishttps://www.pharmaradar360.com/article/pertussis-guidance-data-and-analysis-03c0c3d9c5f593d2PharmaRadar360en2026-09-24T08:30:10.000ZPertussis: guidance, data and analysishttps://www.pharmaradar360.com/article/rubella-confirmed-cases-and-notifications-926536a7ab5f7350PharmaRadar360en2026-09-24T08:30:09.000ZRubella: confirmed cases and notificationshttps://www.pharmaradar360.com/article/pertussis-laboratory-confirmed-cases-reported-in-england-2026-db4e82e10f96250aPharmaRadar360en2026-09-24T08:30:09.000ZPertussis: laboratory confirmed cases reported in England 2026https://www.pharmaradar360.com/article/gram-negative-mrsa-and-mssa-bacteraemia-and-c-difficile-infections-annual-epidem-f5bcd757f0f31131PharmaRadar360en2026-09-24T08:30:09.000ZGram-negative, MRSA and MSSA bacteraemia and C. difficile infections: annual epidemiological commentarieshttps://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-2026-to-2027-quarterly-da-c123be05410e88f7PharmaRadar360en2026-09-24T08:30:08.000ZCover of vaccination evaluated rapidly (COVER) programme 2026 to 2027: quarterly datahttps://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-2025-to-2026-quarterly-da-ec5c68eb5b9089f9PharmaRadar360en2026-09-24T08:30:08.000ZCover of vaccination evaluated rapidly (COVER) programme 2025 to 2026: quarterly datahttps://www.pharmaradar360.com/article/mumps-confirmed-cases-and-notifications-c7fa17868bb576d7PharmaRadar360en2026-09-24T08:30:08.000ZMumps: confirmed cases and notificationshttps://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-statistics-ba0b6fc132b9bc62PharmaRadar360en2026-09-24T08:30:08.000ZCover of vaccination evaluated rapidly (COVER) programme statisticshttps://www.pharmaradar360.com/article/healthcare-associated-infections-hcai-statistics-b7d400e2cae94ffcPharmaRadar360en2026-09-24T08:30:07.000ZHealthcare-associated infections (HCAI) statisticshttps://www.pharmaradar360.com/article/ukhsa-priorities-in-2026-to-2027-1952003048c98805PharmaRadar360en2026-09-24T08:30:06.000ZUKHSA priorities in 2026 to 2027https://www.pharmaradar360.com/article/ukhsa-annual-remit-letters-951394235efaad03PharmaRadar360en2026-09-24T08:30:06.000ZUKHSA annual remit lettershttps://www.pharmaradar360.com/article/healthcare-associated-infections-hcai-qmi-report-3d3a05bef1af6387PharmaRadar360en2026-09-24T08:30:05.000ZHealthcare-associated infections (HCAI) QMI reporthttps://www.pharmaradar360.com/article/survey-of-adult-carers-in-england-2025-to-2026-report-dd94c8c57d1015b9PharmaRadar360en2026-09-24T08:30:04.000ZSurvey of adult carers in England: 2025 to 2026 reporthttps://www.pharmaradar360.com/article/gram-negative-mrsa-and-mssa-bacteraemia-and-c-difficile-infections-annual-epidem-0349e3e77f352fa2PharmaRadar360en2026-09-24T08:30:04.000ZGram-negative, MRSA and MSSA bacteraemia and C. difficile infections: annual epidemiological reports 2022 to 2025https://www.pharmaradar360.com/article/mrsa-bacteraemia-annual-data-41045b47b36919adPharmaRadar360en2026-09-24T08:30:04.000ZMRSA bacteraemia: annual datahttps://www.pharmaradar360.com/article/gram-negative-mrsa-and-mssa-bacteraemia-and-c-difficile-infections-annual-epidem-15eaf59b1e073a25PharmaRadar360en2026-09-24T08:30:04.000ZGram-negative, MRSA and MSSA bacteraemia and C. difficile infections: annual epidemiological commentary 2025 to 2026https://www.pharmaradar360.com/article/zawya-jordan-innovation-to-boost-pharmaceutical-industry-expansion-competitivene-176d20ac670397c0PharmaRadar360en2026-09-24T08:06:40.000ZZAWYA: Jordan: Innovation to boost pharmaceutical industry expansion, competitivenesshttps://www.pharmaradar360.com/article/bristol-myers-squibb-announces-265-additional-job-cuts-9a849e8b43466d86PharmaRadar360en2026-09-24T07:56:21.000ZBristol Myers Squibb announces 265 additional job cutshttps://www.pharmaradar360.com/article/five-reputable-food-safety-pharmaceutical-analysis-testing-comp-8d1fad0593c07239PharmaRadar360en2026-09-24T07:46:09.000ZFive Reputable Food Safety & Pharmaceutical Analysis Testing Comphttps://www.pharmaradar360.com/article/sweden-sees-rise-in-reported-adverse-reactions-to-semaglutide-c726e3240e922ecdPharmaRadar360en2026-09-24T07:32:43.000ZSweden sees rise in reported adverse reactions to semaglutidehttps://www.pharmaradar360.com/article/the-phd-to-biotech-series-clarifying-your-direction-before-you-leave-academia-32528df980be6fabPharmaRadar360en2026-09-24T07:30:00.000ZThe PhD to biotech series: Clarifying your direction before you leave academiahttps://www.pharmaradar360.com/article/klinische-forschung-unter-druck-die-schweiz-verliert-den-anschluss-4d978b99d88debe3PharmaRadar360en2026-09-24T07:12:57.000ZKlinische Forschung unter Druck: Die Schweiz verliert den Anschlusshttps://www.pharmaradar360.com/article/astellas-starts-phase-3-trial-of-setidegrasib-vs-docetaxel-in-kras-g12d-lung-can-04158db7875be88dPharmaRadar360en2026-09-24T06:43:26.000ZAstellas Starts Phase 3 Trial of Setidegrasib vs Docetaxel in KRAS G12D Lung Cancerhttps://www.pharmaradar360.com/article/aurion-biotech-completes-enrolment-in-pivotal-phase-3-astra-trial-of-aurn001-054fc721ae97f0f7PharmaRadar360en2026-09-24T06:41:03.000ZAurion Biotech completes enrolment in pivotal Phase 3 ASTRA trial of AURN001https://www.pharmaradar360.com/article/2026-1816dbb998f2b4ffPharmaRadar360en2026-09-24T06:39:42.000ZΓενόσημα Αυγούστου 2026 _ Προτεινόμενες Τιμές προς Διαβούλευσηhttps://www.pharmaradar360.com/article/lilly-puts-up-100m-plus-billions-on-the-backend-to-form-5-target-deal-with-china-6c61ef54a1649f1cPharmaRadar360en2026-09-24T06:39:26.000ZLilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCarehttps://www.pharmaradar360.com/article/8ebee4139de8b40aPharmaRadar360en2026-09-24T06:36:45.000ZΔήλωση Αποθεμάτων Φαρμάκων Ανθρώπινης Χρήσηςhttps://www.pharmaradar360.com/article/europe-s-opportunity-to-capture-the-value-in-china-biotech-mcdermott-will-schult-085f959c32a8b182PharmaRadar360en2026-09-24T06:36:00.000ZEurope’s opportunity to capture the value in China biotech. McDermott Will & Schulte's Emmanuelle Trombe and Anthony Paronneau talk to Investors in Healthcarehttps://www.pharmaradar360.com/article/iii-imagination-a496c4076e536916PharmaRadar360en2026-09-24T06:30:00.000Zロシュ社によるセーファキセルセンナトリウムに関する発表について（第III相IMAGINATION試験の中間解析結果）https://www.pharmaradar360.com/article/roche-s-announcement-regarding-sefaxersen-announcement-of-interim-analysis-resul-2b62b1533500f4e4PharmaRadar360en2026-09-24T06:30:00.000ZRoche’s Announcement Regarding Sefaxersen (Announcement of Interim Analysis Results from the Phase III IMAGINATION Study)https://www.pharmaradar360.com/article/senators-to-question-fda-nominee-about-her-views-on-abortion-pill-and-vaccines-7927482d11e62167PharmaRadar360en2026-09-24T06:10:03.000ZSenators to question FDA nominee about her views on abortion pill and vaccineshttps://www.pharmaradar360.com/article/us-mrna-player-arcturus-buys-belgian-biotech-myneo-d16ed4fa7c90683bPharmaRadar360en2026-09-24T05:46:56.000ZUS mRNA player Arcturus buys Belgian biotech MyNeohttps://www.pharmaradar360.com/article/from-scientific-excellence-to-industrial-implementation-7d269cad5f6bcd35PharmaRadar360en2026-09-24T05:31:01.000ZFrom Scientific Excellence to Industrial Implementationhttps://www.pharmaradar360.com/article/scancell-completes-up-to-us-25-million-in-debt-financing-providing-optionality-a-bf9b9582e6d48052PharmaRadar360en2026-09-24T05:02:51.000ZScancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 developmenthttps://www.pharmaradar360.com/article/beyond-open-innovation-how-to-make-pharma-biotech-collab-work-at-scale-56c6678157e4dce8PharmaRadar360en2026-09-24T05:00:01.000ZBeyond Open Innovation: How to Make Pharma–Biotech Collab Work at Scalehttps://www.pharmaradar360.com/article/small-biotech-can-outsource-the-work-but-not-the-thinking-62440c8a0f80ffa8PharmaRadar360en2026-09-24T04:48:20.000ZSmall Biotech Can Outsource The Work, But Not The Thinkinghttps://www.pharmaradar360.com/article/oncolytics-biotech-nasdaq-oncy-trading-down-5-2-time-to-sell-0ef78dc82ada9778PharmaRadar360en2026-09-24T04:23:03.000ZOncolytics Biotech (NASDAQ:ONCY) Trading Down 5.2% - Time to Sell?https://www.pharmaradar360.com/article/fda-suspends-licence-of-big-basket-outlet-2-others-in-pune-983a0d3619458216PharmaRadar360en2026-09-24T04:01:00.000ZFDA suspends licence of Big Basket outlet, 2 others in Punehttps://www.pharmaradar360.com/article/forge-nano-and-nanexa-enter-joint-development-agreement-to-advance-manufacturing-ba5c9042fb0dd3d3PharmaRadar360en2026-09-24T03:43:00.000ZForge Nano and Nanexa Enter Joint Development Agreement to Advance Manufacturing for ALD-Coated PharmaShell® Long-Acting Injectable Medicineshttps://www.pharmaradar360.com/article/relay-therapeutics-stock-in-focus-as-phase-3-trial-begins-ae162c061bbbe4dePharmaRadar360en2026-09-24T03:40:53.000ZRelay Therapeutics Stock In Focus As Phase 3 Trial Beginshttps://www.pharmaradar360.com/article/beyond-gravity-what-happens-when-biotech-leaves-earth-f07a29aa63bed1c2PharmaRadar360en2026-09-24T03:19:36.000ZBeyond gravity — What happens when biotech leaves Earth?https://www.pharmaradar360.com/article/pharmaceutical-fine-chemicals-market-research-by-the-business-research-company-h-d995cc154853c988PharmaRadar360en2026-09-24T02:15:00.000ZPharmaceutical Fine Chemicals Market Research By The Business Research Company, Highlights Future Industry Forecastshttps://www.pharmaradar360.com/article/denmark-s-novo-nordisk-drives-pharmaceutical-growth-amid-economi-614c7030a4d75324PharmaRadar360en2026-09-24T01:30:52.000ZDenmark's Novo Nordisk Drives Pharmaceutical Growth Amid Economihttps://www.pharmaradar360.com/article/veraxa-biotech-nasdaq-vrxa-appoints-raju-willener-as-chief-financial-officer-f28b533ec19df462PharmaRadar360en2026-09-24T01:29:31.000ZVERAXA Biotech (NASDAQ: VRXA) Appoints Raju Willener as Chief Financial Officerhttps://www.pharmaradar360.com/article/otsuka-presents-new-phase-3b-results-for-simtriyo-centanafadine-highlighting-con-1a29f0f899bb75bdPharmaRadar360en2026-09-24T01:00:00.000ZOtsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026https://www.pharmaradar360.com/article/south-korea-s-cellid-sells-control-to-huniverse-global-bluemtec-goes-to-kolmar-g-3f9c640f1bbe8a4bPharmaRadar360en2026-09-24T00:55:00.000ZSouth Korea's Cellid Sells Control to Huniverse Global; BlueMTec Goes to Kolmar Grouphttps://www.pharmaradar360.com/article/hlb-wins-fda-nod-for-fgfr2-cholangiocarcinoma-drug-targets-q4-us-launch-chosunbi-1f8b2d48bd4073d8PharmaRadar360en2026-09-24T00:36:00.000ZHLB wins FDA nod for FGFR2 cholangiocarcinoma drug, targets Q4 US launch - CHOSUNBIZhttps://www.pharmaradar360.com/article/kringle-pharma-seeks-u-s-phase-3-trial-for-spinal-cord-injury-drug-14edbc70749803b0PharmaRadar360en2026-09-24T00:33:11.000ZKringle Pharma Seeks U.S. Phase 3 Trial for Spinal Cord Injury Drughttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-d3f013665ddaf50fPharmaRadar360en2026-09-24T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-443ea740c7e69f2ePharmaRadar360en2026-09-24T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-38a38cc651371f60PharmaRadar360en2026-09-24T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-f5553c80e908f2c8PharmaRadar360en2026-09-24T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-06139b71cc0c153bPharmaRadar360en2026-09-24T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-233ae5c1e061737fPharmaRadar360en2026-09-24T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-172118f52588403ePharmaRadar360en2026-09-24T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-713ee91cfbca7345PharmaRadar360en2026-09-24T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-6444b7eb9bd533c5PharmaRadar360en2026-09-24T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-b13e77112b2bd209PharmaRadar360en2026-09-24T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-9a2ffc4b39550df0PharmaRadar360en2026-09-24T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-5d34321111493c16PharmaRadar360en2026-09-24T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-9a0cdccf6bfe7223PharmaRadar360en2026-09-24T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-17a9ae42e7bab440PharmaRadar360en2026-09-24T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/health-center-program-performance-period-extensions-0f0cd04cdb1c8a07PharmaRadar360en2026-09-24T00:00:00.000ZHealth Center Program Performance Period Extensionshttps://www.pharmaradar360.com/article/national-institute-on-deafness-and-other-communication-disorders-notice-of-close-ba042779be6415ecPharmaRadar360en2026-09-24T00:00:00.000ZNational Institute on Deafness and Other Communication Disorders; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/announcement-of-the-intent-to-award-a-single-source-cooperative-agreement-to-int-196740f909292d40PharmaRadar360en2026-09-24T00:00:00.000ZAnnouncement of the Intent To Award a Single-Source Cooperative Agreement to International Rescue Committee in New York, New Yorkhttps://www.pharmaradar360.com/article/improving-patient-access-to-deceased-donor-islet-cells-and-cell-products-request-7c8bf0c1fd2bd478PharmaRadar360en2026-09-24T00:00:00.000ZImproving Patient Access to Deceased Donor Islet Cells and Cell Products; Request for Informationhttps://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-cayman-chemical-company-83551c67b2dddf3ePharmaRadar360en2026-09-24T00:00:00.000ZBulk Manufacturer of Controlled Substances Application: Cayman Chemical Companyhttps://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-eli-elsohly-laboratories-7b874ac6769188b4PharmaRadar360en2026-09-24T00:00:00.000ZBulk Manufacturer of Controlled Substances Application: Eli-Elsohly Laboratorieshttps://www.pharmaradar360.com/article/importer-of-controlled-substances-application-fisher-clinical-services-inc-i-22f4ec8f816e8d51PharmaRadar360en2026-09-24T00:00:00.000ZImporter of Controlled Substances Application: Fisher Clinical Services, Inc. (I)https://www.pharmaradar360.com/article/importer-of-controlled-substances-application-cambridge-isotope-laboratories-inc-339a6737685ac403PharmaRadar360en2026-09-24T00:00:00.000ZImporter of Controlled Substances Application: Cambridge Isotope Laboratories, Inc.https://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-cambridge-isotope-laborat-5e9cedccc508e97dPharmaRadar360en2026-09-24T00:00:00.000ZBulk Manufacturer of Controlled Substances Application: Cambridge Isotope Laboratories, Inc.https://www.pharmaradar360.com/article/request-for-information-medicare-part-d-reasonable-and-relevant-pharmacy-contrac-a32ed7dcd8d4274ePharmaRadar360en2026-09-24T00:00:00.000ZRequest for Information; Medicare Part D Reasonable and Relevant Pharmacy Contracting Standardshttps://www.pharmaradar360.com/article/precision-medicine-in-diffuse-large-b-cell-lymphoma-integrating-molecular-biomar-e12408836930ea28PharmaRadar360en2026-09-24T00:00:00.000ZPrecision medicine in diffuse large B-cell lymphoma: Integrating molecular biomarkers, targeted therapies, and prognostic toolshttps://www.pharmaradar360.com/article/efficacy-of-transcatheter-arterial-embolization-plus-targeted-chemotherapy-for-a-dfcd1446063adaccPharmaRadar360en2026-09-24T00:00:00.000ZEfficacy of transcatheter arterial embolization plus targeted chemotherapy for advanced hepatocellular carcinoma: A case report and literature reviewhttps://www.pharmaradar360.com/article/tubulocystic-renal-cell-carcinoma-with-aggressive-behavior-insights-from-molecul-d6bf7b15a82a28e4PharmaRadar360en2026-09-24T00:00:00.000ZTubulocystic renal cell carcinoma with aggressive behavior-insights from molecular profiling and single-cell analysis: A case reporthttps://www.pharmaradar360.com/article/correlations-of-the-expression-of-akap95-cx43-cpsf5-6-scffbxl2-and-scffbxo31-in-457d4f522a00c9edPharmaRadar360en2026-09-24T00:00:00.000ZCorrelations of the expression of AKAP95, Cx43, CPSF5/6, SCFFBXL2 and SCFFBXO31 in lung cancer tissueshttps://www.pharmaradar360.com/article/peer-review-report-for-effects-of-transcutaneous-electrical-stimulation-on-perip-083d3f36c265066ePharmaRadar360en2026-09-24T00:00:00.000ZPeer Review Report For: Effects of transcutaneous electrical stimulation on peripheral nerve regeneration after digital neurorrhaphy: A randomized clinical trial. [version 4; peer review: 1 approved, 2 approved with reservations]https://www.pharmaradar360.com/article/disrupting-hierarchies-of-knowledge-and-strengthening-collective-wisdom-e4b32b559b1fa8d2PharmaRadar360en2026-09-24T00:00:00.000ZDisrupting Hierarchies of Knowledge and Strengthening Collective Wisdomhttps://www.pharmaradar360.com/article/physical-activity-and-exercise-in-pediatric-oncology-conceptual-distinctions-and-0aa355a994cf5c81PharmaRadar360en2026-09-24T00:00:00.000ZPhysical activity and exercise in pediatric oncology: conceptual distinctions and clinical implicationshttps://www.pharmaradar360.com/article/effectiveness-of-vestibular-electrical-stimulation-combined-with-vestibular-reha-eaef322f5700f043PharmaRadar360en2026-09-24T00:00:00.000ZEffectiveness of vestibular electrical stimulation combined with vestibular rehabilitation in chronic unilateral vestibular hypofunction: A randomized controlled trialhttps://www.pharmaradar360.com/article/41-metabolic-dysregulation-and-immune-activation-in-vitiligo-unveiling-the-mitoc-a1301e9a89728dbfPharmaRadar360en2026-09-24T00:00:00.000Z41 | METABOLIC DYSREGULATION AND IMMUNE ACTIVATION IN VITILIGO: UNVEILING THE MITOCHONDRIAL AND INFLAMMATORY IMPRINT OF DISEASE PATHOGENESIShttps://www.pharmaradar360.com/article/clinical-characteristics-associated-factors-and-mortality-related-factors-of-pne-f48946eb2b5492ddPharmaRadar360en2026-09-24T00:00:00.000ZClinical Characteristics, Associated Factors, and Mortality-Related Factors of Pneumocystis jirovecii Pneumonia in Patients With Systemic Autoimmune Rheumatic Diseases: A Systematic Review and Meta-analysishttps://www.pharmaradar360.com/article/epidemiology-genetics-clinical-characteristics-and-dietary-risk-factors-of-famil-51e317c6f6c3535bPharmaRadar360en2026-09-24T00:00:00.000ZEpidemiology, genetics, clinical characteristics, and dietary risk factors of familial celiac disease in China: A cross-sectional studyhttps://www.pharmaradar360.com/article/areszt-elektroniczny-a-ograniczenie-skali-stosowania-tymczasowego-aresztowania-e7128e91325fe374PharmaRadar360en2026-09-24T00:00:00.000ZAreszt elektroniczny a ograniczenie skali stosowania tymczasowego aresztowaniahttps://www.pharmaradar360.com/article/critical-care-ultrasound-guided-targeted-volume-management-as-precision-medicine-e319763ba39afdc9PharmaRadar360en2026-09-24T00:00:00.000ZCritical Care Ultrasound-Guided Targeted Volume Management as Precision Medicine: Predicting Clinical and Financial Impactshttps://www.pharmaradar360.com/article/antibiotic-prophylaxis-of-infective-endocarditis-in-dentistry-an-update-on-the-e-9e0a810bc5198dd3PharmaRadar360en2026-09-24T00:00:00.000ZAntibiotic Prophylaxis of Infective Endocarditis in Dentistry: An Update on the ESC, AHA, and NICE Guidelineshttps://www.pharmaradar360.com/article/perioperative-outcomes-of-multivessel-minimally-invasive-coronary-revascularizat-9a13b25dc7aea994PharmaRadar360en2026-09-24T00:00:00.000ZPerioperative Outcomes of Multivessel Minimally Invasive Coronary Revascularization at a Specialized Center: A Retrospective Cohort of Complete Surgical and Planned Hybrid Strategieshttps://www.pharmaradar360.com/article/managing-choledocholithiasis-in-rare-congenital-hepatobiliary-anomalies-a-report-acb1ff9b5c98f97cPharmaRadar360en2026-09-24T00:00:00.000ZManaging Choledocholithiasis in Rare Congenital Hepatobiliary Anomalies: A Report of Three Caseshttps://www.pharmaradar360.com/article/handgrip-strength-relative-to-estimated-skeletal-muscle-mass-and-threshold-defin-7cbe553532899c08PharmaRadar360en2026-09-24T00:00:00.000ZHandgrip Strength Relative to Estimated Skeletal Muscle Mass and Threshold-Defined Physical Performance in Biochemically Controlled Acromegaly: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/the-impact-of-changes-to-the-payment-restrictions-of-the-national-reimbursement-2a6860a059aca4d9PharmaRadar360en2026-09-24T00:00:00.000ZThe Impact of Changes to the Payment Restrictions of the National Reimbursement Drug List in China: An Empirical Study Employing a Stacked Difference-in-Differences Approachhttps://www.pharmaradar360.com/article/distinct-molecular-landscape-and-clinical-subtype-of-hpv-positive-esophageal-squ-f21f3f790fac31ebPharmaRadar360en2026-09-24T00:00:00.000ZDistinct Molecular Landscape and Clinical Subtype of HPV-Positive Esophageal Squamous Cell Carcinomahttps://www.pharmaradar360.com/article/psoriasis-and-bullous-pemphigoid-an-updated-review-of-clinical-association-targe-419f7c5d8d17be8aPharmaRadar360en2026-09-24T00:00:00.000ZPsoriasis and Bullous Pemphigoid: An Updated Review of Clinical Association, Targeted Therapy Exposures and Therapeutic Implicationshttps://www.pharmaradar360.com/article/integrated-electrophysiological-and-payload-release-assessment-of-neuronal-respo-f1dfbb664f726b56PharmaRadar360en2026-09-24T00:00:00.000ZIntegrated electrophysiological and payload-release assessment of neuronal responses to antibody-drug conjugates in human iPSC-derived sensory neurons: implications for in vitro neurotoxicity evaluationhttps://www.pharmaradar360.com/article/incidence-burden-and-associated-factors-of-severe-potential-drug-drug-interactio-000263b0d1b1ca97PharmaRadar360en2026-09-24T00:00:00.000ZIncidence, burden, and associated factors of severe potential drug–drug interactions in intensive care unit patients: a real-world retrospective studyhttps://www.pharmaradar360.com/article/clinical-efficacy-and-safety-evaluation-of-dexmedetomidine-hydrochloride-nasal-s-cffd6c1dca84e355PharmaRadar360en2026-09-24T00:00:00.000ZClinical efficacy and safety evaluation of dexmedetomidine hydrochloride nasal spray for sedation before examinations in children aged 2 to 6 years: protocol for a randomized controlled trialhttps://www.pharmaradar360.com/article/strengthening-the-interpretation-of-longitudinal-eqa-data-through-the-sporadic-i-b9fb7e0dd74e7ef1PharmaRadar360en2026-09-24T00:00:00.000ZStrengthening the interpretation of longitudinal EQA data through the sporadic inclusion of native human sera in general clinical chemistryhttps://www.pharmaradar360.com/article/clinical-efficacy-and-pregnancy-outcomes-of-doxycycline-plus-medroxyprogesterone-67f55084828f7378PharmaRadar360en2026-09-24T00:00:00.000ZClinical efficacy and pregnancy outcomes of doxycycline plus medroxyprogesterone acetate therapy for chronic endometritis in women with recurrent reproductive failure: a prospective cohort studyhttps://www.pharmaradar360.com/article/diagnostic-performance-of-digital-and-clinical-approaches-for-detection-of-podoc-e46d474d49be2259PharmaRadar360en2026-09-24T00:00:00.000ZDiagnostic performance of digital and clinical approaches for detection of podoconiosis by community health workers in Rwanda: a comparison with dermatologist diagnosishttps://www.pharmaradar360.com/article/periodic-fever-aphthous-stomatitis-pharyngitis-adenitis-clinical-manifestations-300bd22349cb7d3aPharmaRadar360en2026-09-24T00:00:00.000ZPeriodic fever, aphthous stomatitis, pharyngitis, adenitis: clinical manifestations, response to steroids, and a practice of online diagnosis and follow-uphttps://www.pharmaradar360.com/article/clinical-contribution-of-mngs-in-the-diagnosis-and-management-of-imported-falcip-f7d332a21c9659e8PharmaRadar360en2026-09-24T00:00:00.000ZClinical contribution of mNGS in the diagnosis and management of imported falciparum malaria in a malaria-free region: a five-case series from northern Chinahttps://www.pharmaradar360.com/article/clinical-trials-on-3d-bioprinted-scaffolds-for-lower-extremity-vascular-diabetic-c3b698dce392e375PharmaRadar360en2026-09-24T00:00:00.000ZClinical trials on 3D bioprinted scaffolds for lower extremity vascular, diabetic and pressure ulcers: a systematic reviewhttps://www.pharmaradar360.com/article/nonresponse-to-intravitreal-anti-vegf-therapy-for-retinopathy-of-prematurity-cli-2ab291d4acdae5d7PharmaRadar360en2026-09-24T00:00:00.000ZNonresponse to Intravitreal Anti-VEGF Therapy for Retinopathy of Prematurity: Clinical Characteristics and Outcomes After Retreatmenthttps://www.pharmaradar360.com/article/impact-of-an-oral-amino-acid-containing-formulation-on-clinical-and-functional-o-1593243086615193PharmaRadar360en2026-09-24T00:00:00.000ZImpact of an oral amino acid–containing formulation on clinical and functional outcomes in patients with and without heart failure undergoing cardiac rehabilitation program: a pilot studyhttps://www.pharmaradar360.com/article/dna-methylation-biomarkers-from-precancerous-lesions-to-adenocarcinoma-in-the-st-a86ae7786dc25552PharmaRadar360en2026-09-24T00:00:00.000ZDNA Methylation Biomarkers: From Precancerous Lesions to Adenocarcinoma in the Stomach and Esophagushttps://www.pharmaradar360.com/article/vespula-spp-venom-immunotherapy-basophil-excitability-and-fc-ri-fc-riib-expressi-9fb9de0999d796fePharmaRadar360en2026-09-24T00:00:00.000ZVespula spp. venom immunotherapy: basophil excitability and FcεRI/FcγRIIb expressionhttps://www.pharmaradar360.com/article/effect-of-pea-protein-enriched-snacks-and-vitamin-d-supplementation-on-the-progr-90b2d33384ecf18cPharmaRadar360en2026-09-24T00:00:00.000ZEffect of pea protein-enriched snacks and vitamin D supplementation on the progression of sarcopenia in elderly subjects: study protocol of the SARC-PEA randomised controlled trialhttps://www.pharmaradar360.com/article/local-infiltration-versus-intramuscular-esketamine-for-procedural-pain-and-posto-2318a0d193c092bfPharmaRadar360en2026-09-24T00:00:00.000ZLocal infiltration versus intramuscular esketamine for procedural pain and postoperative PHQ-9 scores in older adults undergoing percutaneous kyphoplasty: a randomised controlled trialhttps://www.pharmaradar360.com/article/comprehensive-evaluation-of-plasma-proteomics-platforms-toward-practical-applica-e7db85d32b44d1b4PharmaRadar360en2026-09-24T00:00:00.000ZComprehensive evaluation of plasma proteomics platforms toward practical applications using accessible mass spectrometry instrumentationhttps://www.pharmaradar360.com/article/clinical-characteristics-and-outcomes-of-hypertrophic-cardiomyopathy-associated-e0f6f3c7bfda81ebPharmaRadar360en2026-09-24T00:00:00.000ZClinical Characteristics and Outcomes of Hypertrophic Cardiomyopathy Associated With Thin Filament Variants: Insights From the SHaRe Registryhttps://www.pharmaradar360.com/article/heterogeneity-of-breast-and-nodal-response-to-neoadjuvant-pembrolizumab-based-ch-f56993f250266eb1PharmaRadar360en2026-09-24T00:00:00.000ZHeterogeneity of breast and nodal response to neoadjuvant pembrolizumab‐based chemoimmunotherapy in early triple‐negative breast cancer and its clinical significancehttps://www.pharmaradar360.com/article/triage-administration-of-ondansetron-for-gastroenteritis-in-children-8cc45fd4d1f1be8dPharmaRadar360en2026-09-24T00:00:00.000ZTriage Administration of Ondansetron for Gastroenteritis in Childrenhttps://www.pharmaradar360.com/article/letter-to-the-editor-an-acceptance-based-healthy-lifestyle-programme-for-communi-9e8b88965342ff19PharmaRadar360en2026-09-24T00:00:00.000ZLetter to the Editor: “An acceptance-based healthy lifestyle programme for community-dwelling patients with pneumoconiosis: A waitlist pilot randomised controlled trial”https://www.pharmaradar360.com/article/psychosocial-and-clinical-factors-associated-with-diabetes-self-management-in-ty-ff48bf860447a18bPharmaRadar360en2026-09-24T00:00:00.000ZPsychosocial and clinical factors associated with diabetes self-management in type 2 diabeteshttps://www.pharmaradar360.com/article/sustained-intravitreal-delivery-of-triamcinolone-acetonide-via-in-situ-forming-l-5c18ed713309c5c3PharmaRadar360en2026-09-24T00:00:00.000ZSustained intravitreal delivery of triamcinolone acetonide via in situ forming lipid liquid crystals: in-vitro and in-vivo evaluationshttps://www.pharmaradar360.com/article/targeting-exosome-conjugated-with-cardiac-homing-peptide-alleviates-myocardial-i-da0e401a6a4a33e0PharmaRadar360en2026-09-24T00:00:00.000ZTargeting exosome conjugated with cardiac homing peptide alleviates myocardial infarction by delivering miRNAshttps://www.pharmaradar360.com/article/analyzing-and-redesigning-deployment-pathways-for-internally-developed-artificia-af509b768608b3f5PharmaRadar360en2026-09-24T00:00:00.000ZAnalyzing and redesigning deployment pathways for internally developed artificial intelligence tools in clinical education and health researchhttps://www.pharmaradar360.com/article/response-to-correspondence-pharmacogenomics-and-digital-adherence-tools-a-commen-ec0f525822d42de2PharmaRadar360en2026-09-24T00:00:00.000ZResponse to Correspondence: Pharmacogenomics and Digital Adherence Tools—A Commentary on Vahdati et al.https://www.pharmaradar360.com/article/supramolecular-salicylic-acid-chemical-peeling-combined-with-supramolecular-acti-b0f0423ae96908ddPharmaRadar360en2026-09-24T00:00:00.000ZSupramolecular Salicylic Acid Chemical Peeling Combined with Supramolecular Active Zinc for Malassezia Folliculitis: Efficacy and Safety from a Multicenter, Single-Arm Trialhttps://www.pharmaradar360.com/article/the-effects-of-coenzyme-q10-supplementation-on-exercise-induced-oxidative-stress-93afc53a8c0ba492PharmaRadar360en2026-09-24T00:00:00.000ZThe effects of coenzyme Q10 supplementation on exercise-induced oxidative stress and related physiological outcomes in athletes: a systematic review and meta-analysishttps://www.pharmaradar360.com/article/integrating-q-rung-picture-fuzzy-hypersoft-sets-with-aczel-alsina-operators-for-5f96258fcdd82d41PharmaRadar360en2026-09-24T00:00:00.000ZIntegrating q-rung picture fuzzy hypersoft sets with Aczel–Alsina operators for pharmaceutical supply chain managementhttps://www.pharmaradar360.com/article/staged-radiotherapy-for-symptomatic-unresectable-giant-hepatic-hemangiomas-with-748970dca67acc07PharmaRadar360en2026-09-24T00:00:00.000ZStaged radiotherapy for symptomatic unresectable giant hepatic hemangiomas with diffuse bilobar involvementhttps://www.pharmaradar360.com/article/establishing-antidiabetic-potential-of-navayasa-churnam-phyto-metabolomics-syste-c0392b5a87139d5dPharmaRadar360en2026-09-24T00:00:00.000ZEstablishing Antidiabetic Potential of Navayasa Churnam: Phyto-Metabolomics, Systems Pharmacology, In Vitro, In Vivo, and In Silico Studieshttps://www.pharmaradar360.com/article/subsequent-depression-in-patients-with-lip-and-head-and-neck-cancer-a-population-d779f0bbe3d24fa6PharmaRadar360en2026-09-24T00:00:00.000ZSubsequent depression in patients with lip and head and neck cancer: a population-based primary care analysishttps://www.pharmaradar360.com/article/correction-to-age-specific-patterns-of-lymph-node-involvement-in-elderly-patient-0db7585dd0d8bb83PharmaRadar360en2026-09-24T00:00:00.000ZCorrection to: Age-specific patterns of lymph node involvement in elderly patients with oral squamous cell carcinoma: a retrospective cohort studyhttps://www.pharmaradar360.com/article/gnal-associated-dystonia-clinical-spectrum-genetic-features-and-genotype-phenoty-89faae5b45271657PharmaRadar360en2026-09-24T00:00:00.000ZGNAL-associated dystonia: clinical spectrum, genetic features, and genotype–phenotype correlationshttps://www.pharmaradar360.com/article/letter-to-the-editor-on-clinical-and-logistical-determinants-of-operative-timing-ec647449118c39c7PharmaRadar360en2026-09-24T00:00:00.000ZLetter to the editor on: “Clinical and logistical determinants of operative timing, surgical approach, and admission in pediatric supracondylar humerus fractures”https://www.pharmaradar360.com/article/correction-to-an-excitation-customized-ict-type-turn-on-probe-for-visualization-e2c8a53da25d0c12PharmaRadar360en2026-09-24T00:00:00.000ZCorrection to: An excitation‑customized ICT‑type turn‑on probe for visualization of cysteine fluctuation in diverse drug‑induced ferroptosis pathwayshttps://www.pharmaradar360.com/article/updated-estimates-of-agreement-between-dispensed-medications-and-forensic-toxico-518bf5af11781f67PharmaRadar360en2026-09-24T00:00:00.000ZUpdated Estimates of Agreement Between Dispensed Medications and Forensic Toxicology in Swedenhttps://www.pharmaradar360.com/article/clinical-management-and-outcomes-of-neonatal-rhinitis-nasal-obstruction-a-scopin-8975fc8cab937599PharmaRadar360en2026-09-24T00:00:00.000ZClinical Management and Outcomes of Neonatal Rhinitis Nasal Obstruction: A Scoping Reviewhttps://www.pharmaradar360.com/article/treatment-duration-and-clinical-response-patterns-of-laryngopharyngeal-reflux-di-94bf8b18875eb65bPharmaRadar360en2026-09-24T00:00:00.000ZTreatment Duration and Clinical Response Patterns of Laryngopharyngeal Reflux Diseasehttps://www.pharmaradar360.com/article/scp-expression-of-concern-scp-randomized-controlled-trial-comparing-ondansetron-aa25d492a6d17cf4PharmaRadar360en2026-09-24T00:00:00.000Z<scp>EXPRESSION OF CONCERN</scp> : Randomized controlled trial comparing ondansetron and placebo for the reduction of spinal anesthesia‐induced hypotension during elective cesarean delivery in Egypthttps://www.pharmaradar360.com/article/virtual-reality-for-anxiety-and-pain-management-in-lower-limb-orthopedic-surgery-8580b8bb44e53af4PharmaRadar360en2026-09-24T00:00:00.000ZVirtual Reality for Anxiety and Pain Management in Lower Limb Orthopedic Surgery Under Spinal Anesthesia: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/cellid-bluemtec-rally-on-change-of-control-deals-inventera-gains-k-bio-pulse-ddd3aa5d40251ec1PharmaRadar360en2026-09-23T23:37:03.000ZCellid, BlueMtec Rally on Change-of-Control Deals; Inventera Gains[K-bio pulse]https://www.pharmaradar360.com/article/astellas-doses-first-patient-in-phase-3-study-of-setidegrasib-in-previously-trea-935385bd343d9a9dPharmaRadar360en2026-09-23T23:30:00.000ZAstellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D- Mutated Advanced Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-i-wst-stock-forecasts-398c8f9315345cfaPharmaRadar360en2026-09-23T23:22:21.000ZWest Pharmaceutical Services, I (WST) Stock Forecastshttps://www.pharmaradar360.com/article/can-this-biotech-innovation-halt-the-destructive-march-of-a-cereal-killer-3d54d3360d238eacPharmaRadar360en2026-09-23T23:00:04.000ZCan this biotech innovation halt the destructive march of a cereal killer?https://www.pharmaradar360.com/article/is-teva-pharmaceutical-industries-teva-undervalued-following-new-phase-3-schizop-d925da119001e5c1PharmaRadar360en2026-09-23T22:33:23.000ZIs Teva Pharmaceutical Industries (TEVA) Undervalued Following New Phase 3 Schizophrenia Data?https://www.pharmaradar360.com/article/phase-3-data-could-make-roche-drug-a-contender-to-treat-rare-kidney-disease-373f4e947a97b2b4PharmaRadar360en2026-09-23T22:14:06.000ZPhase 3 Data Could Make Roche Drug a Contender to Treat Rare Kidney Disease`https://www.pharmaradar360.com/article/stealth-tactic-makes-chemotherapy-smarter-f5c2518014bb4ff0PharmaRadar360en2026-09-23T21:27:03.000ZStealth tactic makes chemotherapy smarterhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-to-report-third-quarter-2026-financial-result-36a5a6e45481d27bPharmaRadar360en2026-09-23T20:50:00.000ZTeva Pharmaceutical Industries Ltd. to Report Third Quarter 2026 Financial Results on November 3, 2026https://www.pharmaradar360.com/article/federal-court-enters-consent-decree-against-gold-star-distribution-inc-following-512ca83e8b0ada73PharmaRadar360en2026-09-23T20:40:16.000ZFederal Court Enters Consent Decree Against Gold Star Distribution, Inc. Following Persistent Insanitary Warehouse Conditionshttps://www.pharmaradar360.com/article/fda-approves-lirafugratinib-for-advanced-fgfr2-cholangiocarcinoma-577ff202acb6b4efPharmaRadar360en2026-09-23T20:17:25.000ZFDA Approves Lirafugratinib for Advanced FGFR2+ Cholangiocarcinomahttps://www.pharmaradar360.com/article/a-share-grant-led-to-a-tax-related-sale-legend-biotech-legn-cfo-received-19-676-63772b78d4a2cd05PharmaRadar360en2026-09-23T20:16:21.000ZA share grant led to a tax-related sale: Legend Biotech (LEGN) CFO received 19,676 shares and sold 5,430.https://www.pharmaradar360.com/article/biotech-stocks-widely-dive-here-are-the-hardest-hit-6f022ab383ea840cPharmaRadar360en2026-09-23T20:12:00.000ZBiotech Stocks Widely Dive. Here Are The Hardest Hit.https://www.pharmaradar360.com/article/zymeworks-completes-acquisition-of-theravance-biopharma-e7abdc6fed51279dPharmaRadar360en2026-09-23T20:02:35.000ZZymeworks Completes Acquisition of Theravance Biopharmahttps://www.pharmaradar360.com/article/statement-on-fda-s-warning-letter-to-empower-pharmacy-for-producing-drug-product-808db959903e7461PharmaRadar360en2026-09-23T19:48:51.000ZStatement on FDA’s Warning Letter to Empower Pharmacy for producing drug products in violation of federal law.https://www.pharmaradar360.com/article/fda-approves-update-for-winrevair-based-on-phase-3-hyperion-trial-data-1de1c592cb071425PharmaRadar360en2026-09-23T18:29:14.000ZFDA Approves Update for Winrevair Based on Phase 3 HYPERION Trial Datahttps://www.pharmaradar360.com/article/karnataka-food-safety-and-drugs-administration-seeks-price-cap-on-essential-medi-5cbb84318e38421dPharmaRadar360en2026-09-23T18:17:00.000ZKarnataka Food Safety and Drugs Administration seeks price cap on essential medical deviceshttps://www.pharmaradar360.com/article/cordis-project-health-active-responsive-materials-development-stability-safety-a-bf4ed37261c96c41PharmaRadar360en2026-09-23T18:06:55.000ZCORDIS project: Health-Active Responsive Materials: Development, Stability, Safety, and Fate Evaluation in Complex Biological Mediahttps://www.pharmaradar360.com/article/cordis-project-from-molecules-to-brain-health-a-framework-for-european-excellenc-4c2ddfe2c9c5c79dPharmaRadar360en2026-09-23T18:05:55.000ZCORDIS project: From Molecules to Brain Health: A Framework for European Excellence in Translational Neurosciencehttps://www.pharmaradar360.com/article/cordis-project-colour-and-patterns-as-fundamental-and-applied-training-playgroun-9a1ed4c01f204816PharmaRadar360en2026-09-23T18:05:10.000ZCORDIS project: Colour and patterns as fundamental and applied training playground for the next generation of leaders in plant breeding and plant researchhttps://www.pharmaradar360.com/article/ai-drug-discovery-s-new-frontier-competing-for-data-assets-virtual-cells-and-org-2cc9bf94b788c23ePharmaRadar360en2026-09-23T18:05:00.000ZAI Drug Discovery's New Frontier: Competing for Data Assets — Virtual Cells and Organoid Chips Move Toward Complementarityhttps://www.pharmaradar360.com/article/cordis-project-european-clinical-research-infrastructure-network-2030-122633066644981bPharmaRadar360en2026-09-23T18:04:52.000ZCORDIS project: European Clinical Research Infrastructure Network 2030https://www.pharmaradar360.com/article/cordis-project-pediatric-clinical-research-infrastructure-service-model-7ce354e83b800a93PharmaRadar360en2026-09-23T18:04:42.000ZCORDIS project: Pediatric clinical Research Infrastructure Service Modelhttps://www.pharmaradar360.com/article/drugmaker-astellas-looks-to-sell-u-s-headquarters-in-northbrook-a5e6a86dc138ed43PharmaRadar360en2026-09-23T18:04:00.000ZDrugmaker Astellas looks to sell U.S. headquarters in Northbrookhttps://www.pharmaradar360.com/article/cordis-project-seizure-cluster-relief-through-smart-therapeutic-management-65b7869edefb7046PharmaRadar360en2026-09-23T18:02:01.000ZCORDIS project: Seizure Cluster Relief through Smart Therapeutic Managementhttps://www.pharmaradar360.com/article/can-this-biotech-innovation-halt-the-destructive-march-of-a-cereal-killer-21dcbc1414047dd9PharmaRadar360en2026-09-23T18:01:35.000ZCan this biotech innovation halt the destructive march of a cereal killer?https://www.pharmaradar360.com/article/cordis-project-cardio-oncology-multidisciplinary-patient-assistance-solution-0fae8f4b4eab75caPharmaRadar360en2026-09-23T18:00:15.000ZCORDIS project: Cardio-Oncology Multidisciplinary Patient ASsistance Solutionhttps://www.pharmaradar360.com/article/is-pharma-s-operating-model-being-rewritten-1bd526557033e831PharmaRadar360en2026-09-23T17:56:48.000ZIs Pharma's Operating Model Being Rewritten?https://www.pharmaradar360.com/article/immunovant-stock-slides-after-biotech-scraps-autoimmune-drug-program-a060f5478bcaac74PharmaRadar360en2026-09-23T17:44:00.000ZImmunovant Stock Slides After Biotech Scraps Autoimmune Drug Programhttps://www.pharmaradar360.com/article/mike-doustdar-open-to-direct-listing-for-novo-shares-pharmexec-fdbd724d0a2d9419PharmaRadar360en2026-09-23T17:29:24.000ZMike Doustdar Open to Direct Listing for Novo Shares | PharmExechttps://www.pharmaradar360.com/article/new-orleans-biotech-informuta-wins-1-25m-nsf-grant-b1d18ceb24c761cbPharmaRadar360en2026-09-23T17:15:08.000ZNew Orleans Biotech Informuta Wins $1.25M NSF Granthttps://www.pharmaradar360.com/article/dr-heidi-overton-to-appear-before-senate-committee-for-confirmation-hearing-as-n-927f5ad766e1ef04PharmaRadar360en2026-09-23T17:13:46.000ZDr. Heidi Overton to appear before Senate committee for confirmation hearing as next FDA commissionerhttps://www.pharmaradar360.com/article/september-highlights-a-defined-path-from-enrollment-to-data-to-regulatory-submis-546ba70def50c57bPharmaRadar360en2026-09-23T16:54:55.000ZSeptember Highlights: A Defined Path from Enrollment to Data to Regulatory Submission, Medtronic & Orchestra at HRX, A Milestone Payment, Healthcare Investor Conferences and Morehttps://www.pharmaradar360.com/article/roche-ionis-rna-drug-scores-in-kidney-disease-study-4f1c7b194b826b87PharmaRadar360en2026-09-23T16:26:52.000ZRoche, Ionis RNA drug scores in kidney disease studyhttps://www.pharmaradar360.com/article/africa-needs-more-medicines-can-its-pharmaceutical-industry-keep-up-9a8de728ab5d07fePharmaRadar360en2026-09-23T16:20:43.000ZAfrica needs more medicines. Can its pharmaceutical industry keep up?https://www.pharmaradar360.com/article/pharma-ai-2026-fall-update-preview-agentic-ai-takes-the-wheel-of-pharmaceutical-eec65fbc2b19e4c5PharmaRadar360en2026-09-23T16:00:00.000ZPharma.AI 2026 Fall Update Preview: Agentic AI Takes the Wheel of Pharmaceutical Intelligencehttps://www.pharmaradar360.com/article/china-issues-new-guidelines-on-fentanyl-related-crimes-clarifies-sentencing-stan-d40ab24fc3aaf703PharmaRadar360en2026-09-23T15:51:00.000ZChina issues new guidelines on fentanyl-related crimes, clarifies sentencing standardshttps://www.pharmaradar360.com/article/pharmap-2027-addresses-the-future-of-pharmaceutical-manufacturing-and-packaging-a24f87902f85969aPharmaRadar360en2026-09-23T15:47:05.000ZPHARMAP 2027 Addresses the Future of Pharmaceutical Manufacturing and Packaginghttps://www.pharmaradar360.com/article/amgen-s-dazodalibep-meets-primary-endpoint-in-phase-3-sjogren-s-trial-86c74bc3b8f5dcadPharmaRadar360en2026-09-23T15:46:56.000ZAmgen's Dazodalibep Meets Primary Endpoint in Phase 3 Sjögren's Trialhttps://www.pharmaradar360.com/article/pharmaceutical-packaging-materials-and-drug-compatibility-2f30272ed752ddb3PharmaRadar360en2026-09-23T15:43:00.000ZPharmaceutical packaging materials and drug compatibilityhttps://www.pharmaradar360.com/article/can-immunotherapy-stop-the-clock-on-type-1-diabetes-01c89bbc9df567f0PharmaRadar360en2026-09-23T15:42:04.000ZCan immunotherapy stop the clock on type 1 diabetes?https://www.pharmaradar360.com/article/37-000-ai-agents-are-running-a-virtual-biotech-at-stanford-aa00bf1f361ce5fePharmaRadar360en2026-09-23T15:41:26.000Z37,000 AI Agents Are Running a Virtual Biotech at Stanfordhttps://www.pharmaradar360.com/article/eli-lilly-vs-pfizer-in-2027-one-is-a-much-better-place-to-park-your-pharmaceutic-4de0a023ca1e4643PharmaRadar360en2026-09-23T15:32:00.000ZEli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Yearhttps://www.pharmaradar360.com/article/9-pharma-leaders-sound-alarm-bells-on-biotech-s-decline-in-europe-8cae6dd44987e769PharmaRadar360en2026-09-23T15:31:59.000Z9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europehttps://www.pharmaradar360.com/article/ubc-okanagan-boosts-biotech-growth-jobs-in-kelowna-b5445b438b22e3dfPharmaRadar360en2026-09-23T15:26:00.000ZUBC Okanagan Boosts Biotech Growth, Jobs in Kelownahttps://www.pharmaradar360.com/article/covid-19-vaccination-vaccine-product-information-2f002a54e328b7a9PharmaRadar360en2026-09-23T15:24:13.000ZCOVID-19 vaccination: vaccine product informationhttps://www.pharmaradar360.com/article/sweden-a-powerhouse-for-early-stage-innovation-32336554ff8d853fPharmaRadar360en2026-09-23T15:19:57.000ZSweden, a Powerhouse for Early Stage Innovationhttps://www.pharmaradar360.com/article/jaguar-health-plunges-59-and-viking-therapeuti-db83db73d7dc3b68PharmaRadar360en2026-09-23T15:14:26.000ZJaguar Health plunges 59% and Viking Therapeuti...https://www.pharmaradar360.com/article/petroliferos-lobo-and-oz-studio-expand-trace-from-petroleum-into-pharmaceutical-d8b3b5494ab74d32PharmaRadar360en2026-09-23T15:06:55.000ZPetrolíferos Lobo and Oz Studio Expand TRACE From Petroleum Into Pharmaceutical and Supplement Traceabilityhttps://www.pharmaradar360.com/article/new-safety-module-in-the-clinical-trials-information-system-ctis-50e683a4919aefcePharmaRadar360en2026-09-23T15:02:00.000ZNew Safety Module in the Clinical Trials Information System (CTIS)https://www.pharmaradar360.com/article/europe-s-pharma-chiefs-warn-bloc-is-losing-innovation-race-dd74789b50fb2c08PharmaRadar360en2026-09-23T14:56:17.000ZEurope’s Pharma Chiefs Warn Bloc is Losing Innovation Racehttps://www.pharmaradar360.com/article/students-fill-high-paying-biotech-jobs-7b177440d9c34a4ePharmaRadar360en2026-09-23T14:52:11.000ZStudents fill high-paying biotech jobshttps://www.pharmaradar360.com/article/expres2ion-biotech-holding-ab-exprs2-secures-sek-19-3m-to-13-exercise-1-1-b1ec93da641bbb8dPharmaRadar360en2026-09-23T14:50:00.000ZExpreS2ion Biotech Holding AB (EXPRS2) Secures ~SEK 19.3M; TO 13 Exercise 1.1%https://www.pharmaradar360.com/article/european-big-pharma-unites-amid-ringing-alarm-bells-of-continents-dominance-42c06e624a767769PharmaRadar360en2026-09-23T13:54:28.000ZEuropean big pharma unites amid ‘ringing alarm bells’ of continents dominancehttps://www.pharmaradar360.com/article/amgen-asset-from-27-8b-horizon-buy-scores-in-phase-3-sjogren-s-study-c6347dd93b97ff66PharmaRadar360en2026-09-23T13:52:45.000ZAmgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren’s studyhttps://www.pharmaradar360.com/article/bit-bio-partners-with-miriamed-to-bring-human-cardiomyocytes-to-its-drug-discove-6dfc3ef16dd20840PharmaRadar360en2026-09-23T13:47:54.000ZBit.bio partners with Miriamed to bring human cardiomyocytes to its drug discovery portfoliohttps://www.pharmaradar360.com/article/enveda-reaps-311m-series-e-to-feed-ambition-to-become-a-household-name-f72260477437e222PharmaRadar360en2026-09-23T13:47:04.000ZEnveda reaps $311M series E to feed ambition to become a ‘household name’https://www.pharmaradar360.com/article/flagship-gets-a-pentagon-contract-fcb7bac7859a0771PharmaRadar360en2026-09-23T13:38:45.000ZFlagship gets a Pentagon contracthttps://www.pharmaradar360.com/article/maia-biotechnology-expands-pivotal-phase-3-thio-104-non-small-cell-lung-cancer-t-410cbc55b527a9d2PharmaRadar360en2026-09-23T13:32:07.000ZMAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugalhttps://www.pharmaradar360.com/article/jedco-innovation-to-boost-jordan-s-pharmaceutical-industry-expansion-competitive-60088197bf5af4b5PharmaRadar360en2026-09-23T13:29:24.000ZJEDCO: Innovation to Boost Jordan’s Pharmaceutical Industry Expansion, Competitivenesshttps://www.pharmaradar360.com/article/public-mental-health-autumn-webinar-school-based-mental-health-interventions-9698cdb22343e0dcPharmaRadar360en2026-09-23T13:28:02.000ZPublic Mental Health Autumn Webinar: School-Based Mental Health Interventionshttps://www.pharmaradar360.com/article/q-a-why-ndc-12-readiness-has-to-happen-before-day-one-b1cd27b1952015f8PharmaRadar360en2026-09-23T13:26:33.000ZQ&A: Why NDC-12 Readiness Has to Happen Before Day Onehttps://www.pharmaradar360.com/article/penny-stock-vistagen-analyst-highlights-caution-after-anxiety-data-608d73e82bd1b1daPharmaRadar360en2026-09-23T13:25:01.000ZPenny Stock Vistagen Analyst Highlights Caution after Anxiety Datahttps://www.pharmaradar360.com/article/about-30-000-new-lung-cancer-cases-occur-yearly-in-spain-and-portugal-a-trial-ha-0bd639da70000348PharmaRadar360en2026-09-23T13:17:00.000ZAbout 30,000 new lung cancer cases occur yearly in Spain and Portugal; a trial has approval to screen patients there.https://www.pharmaradar360.com/article/concord-biotech-announces-1-1-bonus-share-issue-shareholders-to-get-one-free-sha-e452dcfda4d71e2bPharmaRadar360en2026-09-23T13:15:17.000ZConcord Biotech announces 1:1 bonus share issue; shareholders to get one free share for each held - CNBC TV18https://www.pharmaradar360.com/article/rbc-says-ai-weakness-appears-to-be-fueling-biotech-rally-f7ddd140c25173b3PharmaRadar360en2026-09-23T13:13:59.000ZRBC says AI weakness appears to be fueling biotech rallyhttps://www.pharmaradar360.com/article/amylyx-pharmaceuticals-inc-amlx-stock-price-news-quote-and-history-881f9021c1f02419PharmaRadar360en2026-09-23T13:10:50.000ZAmylyx Pharmaceuticals, Inc. (AMLX) stock price, news, quote and historyhttps://www.pharmaradar360.com/article/aurion-biotech-completes-enrollment-in-phase-3-astra-trial-of-aurn001-for-cornea-d5b3dd232e1b81b4PharmaRadar360en2026-09-23T13:09:23.000ZAurion Biotech Completes Enrollment in Phase 3 ASTRA Trial of AURN001 for Corneal Edemahttps://www.pharmaradar360.com/article/enveda-raises-311-million-from-leading-ai-and-biotech-investors-to-bring-pharma-d2d89fe7cfa4c511PharmaRadar360en2026-09-23T13:08:58.000ZEnveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Centuryhttps://www.pharmaradar360.com/article/maharashtra-fda-chief-tukaram-mundhe-welcomes-bollywood-actors-support-for-food-7704108b6ff5afbePharmaRadar360en2026-09-23T13:06:00.000ZMaharashtra FDA chief Tukaram Mundhe welcomes Bollywood actors' support for food safety crackdownhttps://www.pharmaradar360.com/article/new-yorkers-prescribed-generic-drugs-could-be-entitled-to-share-of-96m-settlemen-079f2f04be6ccf19PharmaRadar360en2026-09-23T13:05:58.000ZNew Yorkers Prescribed Generic Drugs Could Be Entitled To Share Of $96M Settlement: AGhttps://www.pharmaradar360.com/article/class-4-medicines-defect-notification-b-braun-melsungen-ag-meropenem-1000-mg-pow-c017a279be305219PharmaRadar360en2026-09-23T13:00:26.000ZClass 4 Medicines Defect Notification: B. Braun Melsungen AG, Meropenem 1000 mg powder and solvent for solution for infusion, EL(26)A/39https://www.pharmaradar360.com/article/two-men-joined-forces-at-a-biotech-firm-one-is-being-hailed-for-his-work-to-cure-b32648efcb588026PharmaRadar360en2026-09-23T13:00:00.000ZTwo Men Joined Forces at a Biotech Firm. One Is Being Hailed for His Work to Cure HIV. The Other Is Going to Prison.https://www.pharmaradar360.com/article/main-sequence-backs-dementia-biotech-kinoxis-in-a-9-25m-round-1e029c7e02718a39PharmaRadar360en2026-09-23T12:53:56.000ZMain Sequence backs dementia biotech Kinoxis in A$9.25M roundhttps://www.pharmaradar360.com/article/maharashtra-tukaram-mundhe-led-fda-expands-food-safety-drive-to-schools-festival-ff43b1c3c042f5f4PharmaRadar360en2026-09-23T12:52:54.000ZMaharashtra: Tukaram Mundhe-Led FDA Expands Food Safety Drive To Schools, Festivals, Pharmacies & Foodhttps://www.pharmaradar360.com/article/anmat-alerta-sobre-solicitudes-de-datos-en-nombre-del-organismo-920bc6d837759649PharmaRadar360en2026-09-23T12:44:16.000ZANMAT alerta sobre solicitudes de datos en nombre del organismohttps://www.pharmaradar360.com/article/anmat-dispuso-la-cancelacion-de-certificados-de-especialidades-medicinales-que-n-878404cca01dfa0ePharmaRadar360en2026-09-23T12:37:54.000ZANMAT dispuso la cancelación de certificados de especialidades medicinales que no fueron reinscriptoshttps://www.pharmaradar360.com/article/cphi-milan-2026-preview-key-themes-and-emerging-trends-64ad898e4b3525cePharmaRadar360en2026-09-23T12:33:06.000ZCPHI Milan 2026 preview: key themes and emerging trendshttps://www.pharmaradar360.com/article/dcoy-stock-whipsaws-as-traders-game-biotech-volatility-f2eafaf137ceaf88PharmaRadar360en2026-09-23T12:33:00.000ZDCOY Stock Whipsaws As Traders Game Biotech Volatilityhttps://www.pharmaradar360.com/article/a-drug-formulation-designed-to-reach-lung-tumors-has-mexican-patent-protection-t-9a6226bbb164d9bePharmaRadar360en2026-09-23T12:29:49.000ZA drug formulation designed to reach lung tumors has Mexican patent protection through 2040.https://www.pharmaradar360.com/article/6-moonshot-biotech-stocks-that-offer-big-risks-bigger-rewards-2ec5afb22e0bf892PharmaRadar360en2026-09-23T12:28:00.000Z6 ‘Moonshot’ Biotech Stocks That Offer Big Risks, Bigger Rewardshttps://www.pharmaradar360.com/article/oppenheimer-initiates-coverage-on-teva-pharmaceutical-industries-nyse-teva-d07bac4ace81e494PharmaRadar360en2026-09-23T12:27:08.000ZOppenheimer Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA)https://www.pharmaradar360.com/article/moleculin-nasdaq-mbrx-lowers-warrant-price-while-stating-it-needs-trial-funding-37feb91e0c967f74PharmaRadar360en2026-09-23T12:25:55.000ZMoleculin (NASDAQ: MBRX) lowers warrant price while stating it needs trial fundinghttps://www.pharmaradar360.com/article/moleculin-biotech-secures-mexican-patent-protecting-lung-targeted-liposomal-anna-72c1ed32316517e8PharmaRadar360en2026-09-23T12:25:00.000ZMoleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040https://www.pharmaradar360.com/article/aurion-biotech-completes-enrollment-in-pivotal-astra-phase-3-study-advancing-aur-900b781ebb8e9b5bPharmaRadar360en2026-09-23T12:19:55.000ZAurion Biotech Completes Enrollment in Pivotal ASTRA Phase 3 Study, Advancing AURN001 Toward Potential New Treatment for Corneal Edema Secondary to Corneal Endothelial Dysfunctionhttps://www.pharmaradar360.com/article/european-pharmaceutical-sector-faces-decline-amid-global-competition-87e90953660cdc78PharmaRadar360en2026-09-23T12:06:21.000ZEuropean Pharmaceutical Sector Faces Decline Amid Global Competitionhttps://www.pharmaradar360.com/article/enveda-raises-311-million-from-leading-ai-and-biotech-investors-to-bring-pharma-dc35a2b891936318PharmaRadar360en2026-09-23T12:00:30.000ZEnveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Centuryhttps://www.pharmaradar360.com/article/williams-cystoscopic-injection-needle-6c20102f9f238606PharmaRadar360en2026-09-23T12:00:00.000ZWilliams Cystoscopic Injection Needlehttps://www.pharmaradar360.com/article/omniasecuretm-mri-surescantm-2d8833077cd38fa9PharmaRadar360en2026-09-23T12:00:00.000ZOmniaSecure™ MRI SureScan™https://www.pharmaradar360.com/article/dcoy-stock-whipsaws-as-traders-target-biotech-volatility-4c2712f525e7e336PharmaRadar360en2026-09-23T11:48:00.000ZDCOY Stock Whipsaws As Traders Target Biotech Volatilityhttps://www.pharmaradar360.com/article/2026-1d5604d4a504007cPharmaRadar360en2026-09-23T11:39:17.000ZΓενόσημα Ιουλίου 2026_Τελικές Προτεινόμενες Τιμέςhttps://www.pharmaradar360.com/article/the-biotech-growth-trust-plc-why-biotech-s-recovery-could-still-have-further-to-310d1862d2e9b283PharmaRadar360en2026-09-23T11:27:10.000ZThe Biotech Growth Trust plc – Why Biotech’s Recovery Could Still Have Further to Run (video)https://www.pharmaradar360.com/article/viking-s-vk2735-shows-durable-weight-loss-with-less-frequent-maintenance-dosing-03f08420126a796fPharmaRadar360en2026-09-23T11:23:18.000ZViking's VK2735 shows durable weight loss with less frequent maintenance dosinghttps://www.pharmaradar360.com/article/oppenheimer-initiates-collegium-pharmaceutical-stock-at-outperform-c9f41444cb0d0522PharmaRadar360en2026-09-23T11:19:54.000ZOppenheimer initiates Collegium Pharmaceutical stock at Outperformhttps://www.pharmaradar360.com/article/bollywood-actors-back-tukaram-mundhe-s-food-safety-drive-fda-chief-says-grateful-d2aaf98462181b67PharmaRadar360en2026-09-23T11:02:00.000ZBollywood actors back Tukaram Mundhe's food safety drive, FDA chief says 'grateful'https://www.pharmaradar360.com/article/scientists-are-testing-an-unexpected-new-weapon-against-screwworm-7d6cd17f448fee72PharmaRadar360en2026-09-23T11:00:47.000ZScientists are testing an unexpected new weapon against screwwormhttps://www.pharmaradar360.com/article/ukhsa-expands-wastewater-surveillance-to-strengthen-early-warning-system-for-dan-cebf5a4b17395e76PharmaRadar360en2026-09-23T11:00:02.000ZUKHSA expands wastewater surveillance to strengthen ‘early warning system’ for dangerous pathogenshttps://www.pharmaradar360.com/article/aurion-biotech-completes-enrollment-in-pivotal-astra-phase-3-study-advancing-aur-b6711b307932a822PharmaRadar360en2026-09-23T11:00:00.000ZAurion Biotech Completes Enrollment in Pivotal ASTRA Phase 3 Study, Advancing AURN001 Toward Potential New Treatment for Corneal Edema Secondary to Corneal Endothelial Dysfunctionhttps://www.pharmaradar360.com/article/henlius-looks-to-us-biotech-for-global-tce-rights-in-amberstone-deal-61b48e357cb64d42PharmaRadar360en2026-09-23T10:35:09.000ZHenlius looks to US biotech for global TCE rights in Amberstone dealhttps://www.pharmaradar360.com/article/jefferies-raises-amgen-stock-price-target-on-drug-trial-success-cc7e529ee5fe6e74PharmaRadar360en2026-09-23T10:21:52.000ZJefferies raises Amgen stock price target on drug trial successhttps://www.pharmaradar360.com/article/roche-proposes-former-takeda-ceo-christoph-weber-for-board-seat-eb5e783eba6901a0PharmaRadar360en2026-09-23T10:11:38.000ZRoche proposes former Takeda CEO Christoph Weber for board seathttps://www.pharmaradar360.com/article/shanghai-henlius-biotech-inc-and-amberstone-biosciences-inc-enter-collaboration-fc21a4575dc1493dPharmaRadar360en2026-09-23T10:05:54.000ZShanghai Henlius Biotech, Inc. And Amberstone Biosciences, Inc. Enter Collaboration And License Agreement For Two T Cell Engager Productshttps://www.pharmaradar360.com/article/ai-biotech-startup-enveda-doubles-in-value-to-2-billion-wsj-2a17d33df3769840PharmaRadar360en2026-09-23T10:03:47.000ZAI biotech startup Enveda doubles in value to $2 billion - WSJhttps://www.pharmaradar360.com/article/abortion-statistics-user-engagement-plan-65fe5013a86b6246PharmaRadar360en2026-09-23T10:00:04.000ZAbortion statistics user engagement planhttps://www.pharmaradar360.com/article/abortion-statistics-in-england-and-wales-62845a4d19ed888cPharmaRadar360en2026-09-23T10:00:04.000ZAbortion statistics in England and Waleshttps://www.pharmaradar360.com/article/exclusive-ai-biotech-enveda-doubles-in-value-to-2-billion-a869218d6b806c02PharmaRadar360en2026-09-23T10:00:00.000ZExclusive | AI Biotech Enveda Doubles in Value to $2 Billionhttps://www.pharmaradar360.com/article/jimmy-kimmel-trolls-trump-s-allies-with-parody-pharmaceutical-ad-b474764485d9f9c8PharmaRadar360en2026-09-23T09:59:51.000ZJimmy Kimmel trolls Trump's allies with parody pharmaceutical adhttps://www.pharmaradar360.com/article/polyurethane-tubing-for-biotech-market-to-2035-biopharma-capacity-expansion-driv-2c9779b6fa8fae8dPharmaRadar360en2026-09-23T09:46:23.000ZPolyurethane Tubing for Biotech Market To 2035: Biopharma Capacity Expansion Drives Growth - News and Statisticshttps://www.pharmaradar360.com/article/pharmaceutical-companies-push-trump-administration-to-protect-china-deals-40671ca1388c0776PharmaRadar360en2026-09-23T09:42:10.000ZPharmaceutical Companies Push Trump Administration to Protect China Dealshttps://www.pharmaradar360.com/article/pune-fda-suspends-licences-of-rangla-punjab-manisha-dosa-center-over-safety-viol-27217126f6acd7c7PharmaRadar360en2026-09-23T09:40:35.000ZPune: FDA Suspends Licences Of Rangla Punjab & Manisha Dosa Center Over Safety Violationshttps://www.pharmaradar360.com/article/nine-european-pharma-chairs-warn-of-slow-agony-as-investment-slips-1254cc631db64b03PharmaRadar360en2026-09-23T09:22:06.000ZNine European pharma chairs warn of 'slow agony' as investment slipshttps://www.pharmaradar360.com/article/otsuka-and-ionis-report-positive-phase-iii-readout-for-ulefnersen-36ca2d60798ce8dfPharmaRadar360en2026-09-23T09:22:06.000ZOtsuka and Ionis report positive Phase III readout for ulefnersenhttps://www.pharmaradar360.com/article/drugmakers-biotech-vcs-show-reinvigorated-interest-in-osteoporosis-treatments-ed6a223fc4d8d0a9PharmaRadar360en2026-09-23T09:15:45.000ZDrugmakers, biotech VCs show ‘reinvigorated’ interest in osteoporosis treatmentshttps://www.pharmaradar360.com/article/doustdar-on-plunging-share-price-reflects-level-of-confidence-in-the-company-and-73e26491eface571PharmaRadar360en2026-09-23T09:04:22.000ZDoustdar on plunging share price: Reflects level of confidence in the company and its CEOhttps://www.pharmaradar360.com/article/field-safety-notices-14-to-18-september-2026-e1fc284848d2c91cPharmaRadar360en2026-09-23T09:03:48.000ZField Safety Notices: 14 to 18 September 2026https://www.pharmaradar360.com/article/transparency-data-mhra-performance-data-d981698b76b6bbf6PharmaRadar360en2026-09-23T09:00:20.000ZTransparency data: MHRA Performance Datahttps://www.pharmaradar360.com/article/keep-britain-working-20e801e2a2496745PharmaRadar360en2026-09-23T08:58:51.000ZKeep Britain Workinghttps://www.pharmaradar360.com/article/ionis-pharmaceuticals-phase-3-kidney-trial-meets-proteinuria-endpoint-a1f79eed08f46dc9PharmaRadar360en2026-09-23T08:58:19.000ZIonis Pharmaceuticals' Phase 3 kidney trial meets proteinuria endpointhttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32PharmaRadar360en2026-09-23T08:56:55.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/fullgoal-fund-management-co-ltd-fullgoal-hang-seng-biotech-index-etf-159132-sz-i-566836e7c8e4c8f8PharmaRadar360en2026-09-23T08:56:19.000ZFullgoal Fund Management Co. Ltd - Fullgoal Hang Seng Biotech Index ETF (159132.SZ) income statementhttps://www.pharmaradar360.com/article/innovation-must-remain-at-the-heart-of-pandemic-prevention-preparedness-and-resp-3432662b985a1270PharmaRadar360en2026-09-23T08:22:29.000ZInnovation must remain at the heart of pandemic prevention, preparedness, and response, says pharma industryhttps://www.pharmaradar360.com/article/vaccine-update-issue-376-september-2026-d78aba8959192ee6PharmaRadar360en2026-09-23T08:19:03.000ZVaccine update: issue 376, September 2026https://www.pharmaradar360.com/article/top-10-pharmaceutical-manufacturing-leaders-bfa3f2c240dbd84fPharmaRadar360en2026-09-23T08:18:48.000ZTop 10: Pharmaceutical Manufacturing Leadershttps://www.pharmaradar360.com/article/testo-at-cphi-2026-in-milan-digital-monitoring-for-the-pharmaceutical-industry-51206cd2f0198a2fPharmaRadar360en2026-09-23T08:00:00.000ZTesto at CPHI 2026 in Milan: digital monitoring for the pharmaceutical industryhttps://www.pharmaradar360.com/article/redweiler-480g-red-punch-redweiler-480g-orange-redweiler-480g-cola-tcm-120-mega-f98b8409bad1dccePharmaRadar360en2026-09-23T07:53:29.000ZΑπαγόρευση διάθεσης και διακίνησης των συμπληρωμάτων διατροφής REDWEILER 480G red punch, REDWEILER 480G orange, REDWEILER 480G cola, TCM 120 MEGA capshttps://www.pharmaradar360.com/article/annual-flu-programme-8d7750db1c23f662PharmaRadar360en2026-09-23T07:48:01.000ZAnnual flu programme